Overview

Agent-first workspace for failure claims, preprint watch, and biomedical evidence search.

Ask Claidex

Start with any drug, target, trial, failure pattern, or preprint signal.

Compass: Clinical Trial Navigator

Free clinical trial navigator for clinics. Paste a patient profile to get matched open trials, logistics, and failure context.

Open Compass

Failure Claims

Indexed failure dossiers with primary-source backing. Click a row for the full claim card.

	Title		Target		Trial	Phase	Failure
Jul 1, 2026	Etrasimod in Crohn's disease: CULTIVATE stops after the S1P modulator matches placebo	Etrasimod (APD334)	S1PR1	Pfizer	NCT04173273	Phase 2/Phase 3	Efficacy	MRS 30	Immunology
Jul 1, 2026	Magrolimab in classic Hodgkin lymphoma: a responding trial closed when the CD47 program collapsed	Magrolimab (Hu5F9-G4)	CD47	Ranjana Advani (Stanford University), with Merck Sharp & Dohme	NCT04788043	Phase 2	Sponsor	MRS 27	Oncology
Jun 30, 2026	Lebrikizumab in asthma: an anti-IL-13 effect that would not replicate	Lebrikizumab	IL13	Hoffmann-La Roche	NCT01875003	Phase 3	Efficacy	MRS 37	Immunology
Jun 30, 2026	Valiltramiprosate (ALZ-801) in APOE4/4 Alzheimer's: the oral anti-oligomer bet winds down	Valiltramiprosate (ALZ-801)	APP	Alzheon Inc.	NCT06304883	Phase 3	Efficacy	MRS 34	Neurology
Jun 30, 2026	Belapectin in MASH cirrhosis: a subgroup that did not survive its own confirmatory trial	Belapectin (GR-MD-02)	LGALS3	Galectin Therapeutics Inc.	NCT04365868	Phase 2/3	Efficacy	MRS 42	Cardiology
Jun 29, 2026	Brensocatib in hidradenitis suppurativa: a DPP1 inhibitor that worked in bronchiectasis and lost to placebo here	Brensocatib	CTSC	Insmed Incorporated	NCT06685835	Phase 2	Efficacy	MRS 41	Other
Jun 29, 2026	SAR442501 in achondroplasia: an anti-FGFR3 antibody dropped at 16 patients in a crowded field	SAR442501	FGFR3	Sanofi	NCT06067425	Phase 2	Sponsor	MRS 22	Other
Jun 26, 2026	Pegargiminase in leiomyosarcoma: ARGSARC ends a Phase 3 where the active arm gave up chemotherapy	Pegargiminase (ADI-PEG 20)	ASS1	Polaris Group	NCT05712694	Phase 3	Efficacy	MRS 46	Oncology

1–8 of 85

Preprint Watch

Latest bioRxiv preprints flagged against the clinical failure record. Click a row for the full preprint card.

	Title		Disease			DOI
Jun 26, 2026	Bispecific Antibody Architecture and TNFRSF Target Selection Determine CD8+ T Cell Differentiation and Anti-tumour Immunity	TNFRSF9	Solid tumours (B7-H3-positive; CD8+ T cell co-stimulation)	2 prior	Moderate	10.64898/2026.06.19.732642
Jun 24, 2026	AI-Guided Discovery of Small Molecule LILRB4 (ILT3) Inhibitors Reprograms Microglia and Reduces Amyloid Pathology	LILRB4	Alzheimer's disease	1 prior	Mild	10.64898/2026.06.12.731845
Jun 24, 2026	From DNA-Encoded Library (DEL) Screening to In Vivo Validation: LILRB4 (ILT3)-Targeted Small Molecules Reprograms Myeloid Immune Suppression	LILRB4	Alzheimer's disease	1 prior	Mild	10.64898/2026.06.10.731267
Jun 20, 2026	CRISPR/Cas9-based knockout screening revealed GSK3beta as a key regulator for structural plasticity of axon initial segment	GSK3B	—	1 prior	Mild	10.64898/2026.05.21.726787
Jun 20, 2026	Region-specific regulation of glucocorticoid and mineralocorticoid receptor signaling in a mouse model of oral contraceptive exposure	NR3C1	—	1 prior	Moderate	10.64898/2026.06.15.731933
Jun 17, 2026	GPCR-mediated regulation of glial TNF production	TNF	Glial neuroinflammation (TNF regulation)	1 prior	Moderate	10.64898/2026.06.12.731854
Jun 17, 2026	Effects of oxidative stress and aging on nerve, muscle, and synapse in a male-specific abdominal neuromuscular junction in Drosophila	SOD1	Amyotrophic lateral sclerosis (SOD1 oxidative-stress model)	1 prior	Moderate	10.64898/2026.06.10.731480
Jun 15, 2026	Systematic AI-Driven Drug Repurposing via Clinical Trial Data Mining: A Framework and Six Cross-Therapeutic Case Studies.	TNF	Early-stage neurodegeneration (repurposing hypothesis)	1 prior	Moderate	10.64898/2026.06.11.731629

1–8 of 27